Literature DB >> 2708548

Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects.

P E Nolan1, F I Marcus, B L Erstad, G L Hoyer, C Furman, E B Kirsten.   

Abstract

Previous reports have suggested an interaction between propafenone and digoxin. We investigated the pharmacokinetics of IV digoxin when given alone (Phase I), after pretreatment with propafenone 150 mg every 8 hours for seven days (Phase II), and after propafenone 300 mg every 8 hours for 7 days (Phase III). The total body clearance of digoxin during Phase I was 2.45 ml/min/kg and was 2.17 ml/min/kg during Phase II (NS) and decreased to 1.92 ml/min/kg during Phase III (P less than 0.05). The renal clearance and half-life of digoxin were not significantly altered by propafenone. There was a trend towards a decrease in the volume of distribution of digoxin from 9.43 L/kg in Phase I, to 9.33 L/kg in Phase II, and 8.02 L/kg in Phase III. Similarly there was a trend towards a decreased nonrenal clearance of digoxin from 1.21 ml/min/kg during Phase I to 1.01 ml/min/kg during Phase II and to 0.75 ml/min/kg during Phase III. The changes in volume of distribution and nonrenal clearance parallel each other resulting in no change in the elimination half-life of digoxin. It is postulated that the mechanism of this interaction is due to decreases in the volume of distribution and nonrenal elimination of digoxin by propafenone. The degree of this interaction was related to the dose of propafenone. The magnitude of this interaction may be greater in patients and, thus, may require a reduction in the digoxin dose.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2708548     DOI: 10.1002/j.1552-4604.1989.tb03236.x

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  9 in total

Review 1.  Genetically determined adverse drug reactions involving metabolism.

Authors:  M S Lennard
Journal:  Drug Saf       Date:  1993-07       Impact factor: 5.606

Review 2.  Importance of multi-p450 inhibition in drug-drug interactions: evaluation of incidence, inhibition magnitude, and prediction from in vitro data.

Authors:  Nina Isoherranen; Justin D Lutz; Sophie P Chung; Houda Hachad; Rene H Levy; Isabelle Ragueneau-Majlessi
Journal:  Chem Res Toxicol       Date:  2012-09-27       Impact factor: 3.739

3.  Characterisation of (R/S)-propafenone and its metabolites as substrates and inhibitors of P-glycoprotein.

Authors:  Iouri Bachmakov; Sabine Rekersbrink; Ute Hofmann; Michel Eichelbaum; Martin F Fromm
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-04-15       Impact factor: 3.000

Review 4.  Antiarrhythmic agents: drug interactions of clinical significance.

Authors:  T C Trujillo; P E Nolan
Journal:  Drug Saf       Date:  2000-12       Impact factor: 5.606

Review 5.  Advances in the management of digoxin toxicity in the older patient.

Authors:  S W Borron; C Bismuth; J Muszynski
Journal:  Drugs Aging       Date:  1997-01       Impact factor: 3.923

Review 6.  Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective.

Authors:  Kunal S Taskar; Xinning Yang; Sibylle Neuhoff; Mitesh Patel; Kenta Yoshida; Mary F Paine; Kim L R Brouwer; Xiaoyan Chu; Yuichi Sugiyama; Jack Cook; Joseph W Polli; Imad Hanna; Yurong Lai; Maciej Zamek-Gliszczynski
Journal:  Clin Pharmacol Ther       Date:  2022-06-22       Impact factor: 6.903

Review 7.  Propafenone. A reappraisal of its pharmacology, pharmacokinetics and therapeutic use in cardiac arrhythmias.

Authors:  H M Bryson; K J Palmer; H D Langtry; A Fitton
Journal:  Drugs       Date:  1993-01       Impact factor: 9.546

Review 8.  Cardiac glycosides. Drug interactions of clinical significance.

Authors:  B Magnani; P L Malini
Journal:  Drug Saf       Date:  1995-02       Impact factor: 5.606

Review 9.  Clinical pharmacokinetics of propafenone.

Authors:  J T Hii; H J Duff; E D Burgess
Journal:  Clin Pharmacokinet       Date:  1991-07       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.